Clinical Trials Logo

Compensated Cirrhosis clinical trials

View clinical trials related to Compensated Cirrhosis.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04160897 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis

Start date: October 22, 2019
Phase:
Study type: Observational

The current first-line treatment for HBV is long-term oral antiviral drugs to inhibit HBV DNA replication. First-line antiviral drugs recommended by the Chinese 2015 Hepatitis B Guidelines include ETV and TDF. This study is based on a real-world clinical cohort to retrospectively analyze the effects of ETV and TDF on the long-term (5-year) incidence of HCC in Chinese patients with chronic hepatitis B with compensated cirrhosis. The results will guide the revision of the Chinese HBV guidelines.